- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01357759
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
November 13, 2015 updated by: Morphotek
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis
This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zuidlaren, Netherlands
- Pharmaceutical Research Associates Group B.V.
-
-
-
-
California
-
Los Angeles, California, United States, 90036
- Axis Clinical Trials
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Seaview Jacksonville, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Lynn Health Science Institute
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria for Rheumatoid Arthritis (RA) Subjects:
- Male or female subjects age greater than or equal to 18 years and less than or equal to 75 years.
- Subjects with RA diagnosis per the 2010 Rheumatoid Arthritis Classification Criteria per American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR.)
- BMI less than or equal to 35 kg/m2 at Screening.
- Active RA characterized by DAS28 score of less than or equal to 5.1 at Screening.
- Have been stabilized on their current dose (up to 25 mg/week) of methotrexate(MTX) for at least 4 weeks before randomization.
Exclusion Criteria for Rheumatoid Arthritis (RA)Subjects:
- Subjects with severe active RA and are not on a stable therapeutic regimen at Screening.
- Subjects without significant articular RA.
- Relevant history of significant respiratory disease (e.g., chronic bronchitis, asthma in last 5 years, chronic obstructive pulmonary disease, tuberculosis, interstitial lung disease, such as pneumonitis and pulmonary alveolar proteinosis, as well as significant inhalation exposure to silicon and other substances) that required treatment and/or follow up under the direction of a physician.
- Presence of GM-CSF autoantibodies above normal at Screening.
- Abnormal chest x-ray or PFTs as judged by the investigator at Screening as clinically significant.
- Positive Quantiferon test.
- History of clinically relevant hypersensitivity reactions (e.g., to gold therapy)
- History of medication use that might have carryover effects during the study.
- Previous administration of a GM-CSF modulator within 6 months of randomization, or previous administration of a monoclonal antibody or immunoglobulin fusion protein that is not (or worded as "other than") a GM-CSF modulator within 3 months of randomization.
- Use of any biological therapy other than the test article during the study (informed consent to termination visit)
- Subjects who consume greater than 14 alcoholic drinks per week for males or 7 alcoholic drinks per week for females.
- Weight greater than 120 kg at Screening.
- Use of parenteral and/or intra-articular steroids, immunosuppressants, investigational drugs, and oral anticoagulant drugs within 4 weeks prior to randomization. Oral steroid treatment is permitted if the dosage is less than or equal to 10 mg of prednisone daily, is stable for a minimum of 4 weeks before the study and remains unchanged throughout the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Escalating doses of MORAb-022
Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
|
IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.;
IV infusion of Placebo (saline)
|
Placebo Comparator: Placebo
Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
|
IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.;
IV infusion of Placebo (saline)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety to measures to include adverse events, clinical laboratory results, vital signs, ECGs, physical examinations, local tolerability at the infusion site single escalating intravenous (IV) doses of MORAb-022 in healthy subjects and subjects with RA.
Time Frame: Approximately 113 days
|
Approximately 113 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lydie Hazan, MD, Axis Clinical Trials
- Principal Investigator: Alan J. Kivitz, MD, CPI, Altoona Center for Clinical Research
- Principal Investigator: Chrysoula Pappa, MD, Seaview Jacksonville, LLC
- Principal Investigator: William M Schnitz, MD, Lynn Health Science Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
July 1, 2014
Study Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
May 18, 2011
First Submitted That Met QC Criteria
May 19, 2011
First Posted (Estimate)
May 23, 2011
Study Record Updates
Last Update Posted (Estimate)
November 16, 2015
Last Update Submitted That Met QC Criteria
November 13, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MORAB022-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on MORAb-022
-
Eisai Co., Ltd.Completed
-
Eisai Co., Ltd.Completed
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Antengene Biologics LimitedRecruitingAdvanced/Metastatic Solid TumorsChina, Australia
-
Beijing InnoCare Pharma Tech Co., Ltd.Completed
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingMantle Cell LymphomaChina
-
MorphotekTerminatedMetastatic Colorectal Cancer | Colorectal CancerUnited States
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingPCNSL | Secondary Central Nervous System LymphomaChina
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruiting
-
Shandong UniversityNot yet recruitingImmune Thrombocytopenia | Bruton's Tyrosine Kinase